Mostrar el registro sencillo del ítem

dc.contributor.authorGonzalez-Perez, Maria 
dc.contributor.authorSanchez-Tarjuelo, Rodrigo
dc.contributor.authorShor, Boris
dc.contributor.authorNistal-Villan, Estanislao
dc.contributor.authorOchando, Jordi 
dc.date.accessioned2021-04-06T11:01:12Z
dc.date.available2021-04-06T11:01:12Z
dc.date.issued2021
dc.identifier.citationFront Immunol . 2021 Mar 8;12:632478es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/12525
dc.description.abstractDespite of the rapid development of the vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it will take several months to have enough doses and the proper infrastructure to vaccinate a good proportion of the world population. In this interim, the accessibility to the Bacille Calmette-Guerin (BCG) may mitigate the pandemic impact in some countries and the BCG vaccine offers significant advantages and flexibility in the way clinical vaccines are administered. BCG vaccination is a highly cost-effective intervention against tuberculosis (TB) and many low-and lower-middle-income countries would likely have the infrastructure, and health care personnel sufficiently familiar with the conventional TB vaccine to mount full-scale efforts to administer novel BCG-based vaccine for COVID-19. This suggests the potential for BCG to overcome future barriers to vaccine roll-out in the countries where health systems are fragile and where the effects of this new coronavirus could be catastrophic. Many studies have reported cross-protective effects of the BCG vaccine toward non-tuberculosis related diseases. Mechanistically, this cross-protective effect of the BCG vaccine can be explained, in part, by trained immunity, a recently discovered program of innate immune memory, which is characterized by non-permanent epigenetic reprogramming of macrophages that leads to increased inflammatory cytokine production and consequently potent immune responses. In this review, we summarize recent work highlighting the potential use of BCG for the treatment respiratory infectious diseases and ongoing SARS-CoV-2 clinical trials. In situations where no other specific prophylactic tools are available, the BCG vaccine could be used as a potential adjuvant, to decrease sickness of SARS-CoV-2 infection and/or to mitigate the effects of concurrent respiratory infections.es_ES
dc.description.sponsorshipThe authors' work is supported by National Institutes of Health grants R01 AI139623AI and Ministerio de Ciencia e Innovación PID2019-110015RB-I00 (JO); PID2019-105761RB-100 (EN-V). MG-P is funded from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement no. 860003.es_ES
dc.language.isoenges_ES
dc.publisherFrontiers Media es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectBacille Calmette-Guerines_ES
dc.subjectSARS-CoV-2es_ES
dc.subjectCross-protectiones_ES
dc.subjectTrained immunityes_ES
dc.subjectVaccinationes_ES
dc.titleThe BCG Vaccine for COVID-19: First Verdict and Future Directions.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID33763077es_ES
dc.format.volume12es_ES
dc.format.page632478es_ES
dc.identifier.doi10.3389/fimmu.2021.632478es_ES
dc.contributor.funderNational Institutes of Health (Estados Unidos) 
dc.contributor.funderMinisterio de Ciencia e Innovación (España) 
dc.contributor.funderUnión Europea. Comisión Europea. H2020 
dc.description.peerreviewedes_ES
dc.identifier.e-issn1664-3224es_ES
dc.relation.publisherversionhttps://doi.org/10.3389/fimmu.2021.632478es_ES
dc.identifier.journalFrontiers in immunologyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PID2019-110015RB-I00es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PID2019-105761RB-100es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/860003es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional